Announcing Keystone Symposia’s 2015 conference on:

The Crossroads of Lipid Metabolism and Diabetes

April 19–24, 2015
Tivoli Hotel and Congress Center
Copenhagen, Denmark

Scientific Organizers: Russell A. DeBose-Boyd, Sudha Biddinger and Alan D. Attie

Lead sponsor: Novo Nordisk A/S
Other sponsor: Pfizer Inc.

The prevalence of obesity and Type 2 diabetes is reaching epidemic proportions worldwide. One of the key features of these insulin-resistant disorders is disturbances in lipid metabolism. The goal of this meeting is to provide attendees with insight into the latest advances in the understanding of mechanisms governing the metabolism of lipids and how these pathways become dysregulated in the insulin-resistant state. Elucidation of mechanisms underlying lipid metabolism may reveal new therapeutic strategies to combat atherosclerosis and other complications of diabetic patients. This program should stimulate interactions that are likely to augment and accelerate this process.

Session Topics:
• Reverse Cholesterol Transport
• Regulators and Arbiters of Lipoprotein Metabolism
• Novel Pathways and Targets in Metabolic Disease
• Insulin Control of Lipid Metabolism
• Transcriptional Regulators of Lipid Metabolism
• Nutrient Control of Lipid Metabolism
• Cellular Control of Lipid Synthesis
• Therapeutic Targets for Molecular Disease
KEYSTONE SYMPOSIA  
on Molecular and Cellular Biology  
The Crossroads of Lipid Metabolism and Diabetes (D6)  
April 19-24, 2015 • Tivoli Hotel and Congress Center • Copenhagen, Denmark  
Scientific Organizers: Russell A. DeBose-Boyd, Sudha Biddinger and Alan D. Attie  
Lead Sponsor: Novo Nordisk A/S. Other Sponsors: MedImmune, Merck & Co., Inc. and Pfizer Inc.  

SUNDAY, APRIL 19
Arrival and Registration

MONDAY, APRIL 20
Welcome Remarks
* Alan D. Attie, University of Wisconsin-Madison, USA
Anders Nykjaer, Aarhus University, Denmark
Living in a Butter Well

Keynote Address
Joseph L. Witztum, University of California, San Diego, USA
Lipoprotein Oxidation and Atherosclerosis

LXR in Lipid Metabolism
*Cynthia Hong, Pfizer, USA
Alan R. Tall, Columbia University, USA
TTC39B Modulates LXR, HDL Levels, Atherosclerosis and Steato-Hepatitis
Ira G. Schulman, University of Virginia Health System, USA
Control of Cholesterol Transport and HDL Function by Liver X Receptors
Christopher K. Glass, University of California, San Diego, USA
Regulation of the LXR/SREBP Axis in Macrophages
Noam Zelcer, Academic Medical Center, University of Amsterdam, Netherlands
Short Talk: USP2 Regulates the LDLR Pathway through Deubiquitylation of the E3-Ubiquitin Ligase IDOL

Regulators and Arbiters of Lipoprotein Metabolism
* Alan R. Tall, Columbia University, USA
Anders Nykjaer, Aarhus University, Denmark
Sortilin Receptors in Regulation of Cholesterol and Glucose Metabolism
Jeffrey Esko, University of California, San Diego, USA
Apol-III In Triglyceride-Rich Lipoprotein Clearance
Nabil G. Seidah, Clinical Research Institute of Montreal, Canada
The Biology and Pathophysiology of PCSK9

Poster Session 1

TUESDAY, APRIL 21
Insulin and Bile Acid Signaling
*Morris J. Birnbaum, University of Pennsylvania and Pfizer, Inc.
Sudha B. Biddinger, Boston Children's Hospital, Harvard Medical School, USA
Flavin-Containing Monoxygenase 3 as a Novel Player in Diabetes-Associated Cardiovascular Disease
Domenico Accili, Columbia University, USA
Bile Acids and Insulin Signaling
Fredrik Bäckhed, University of Gothenburg, Sweden
Interaction between Bile Acids and Gut Microbiome in Relation to Host Metabolism

David J. Mangelsdorf, University of Texas Southwestern Medical Center, USA
Dissecting the Tissue-Specific Actions of Endocrine FGF Signaling
Anna Worthington, University Medical Center Hamburg-Eppendorf, Germany
Short Talk: Brown Adipose Tissue Activation Regulates Bile Acid Metabolism and Shapes the Gut Microbiome
Mete Civelek, University of Virginia, USA
Short Talk: Systems Genetics Analyses of Human Adipose Tissue Gene Expression Identify KLF14-Driven Trans Regulatory Transcript Network for Metabolic Disorders

Insulin Control of Lipid Metabolism
* Fabienne Foufelle, Centre de Recherches des Cordeliers, France
Morris J. Birnbaum, University of Pennsylvania and Pfizer, Inc.
The Regulation of Adipocyte Lipolysis by Insulin
C. Ronald Kahn, Joslin Diabetes Center and Harvard Medical School, USA
Lessons about the Biology of Adipose Tissue and Insulin Resistance from Novel Models of Lipodystrophy
Manju Kumari, Beth Israel Deaconess Medical Center, USA
Short Talk: Role of IRF3 in Glucose and Energy Metabolism

Poster Session 2

WEDNESDAY, APRIL 22
Genes Affecting Lipid Metabolism and Diabetes Susceptibility
*C. Ronald Kahn, Joslin Diabetes Center and Harvard Medical School, USA
Alan D. Attie, University of Wisconsin-Madison, USA
Markus Stoffel, ETH Zürich, Switzerland
Foxa2 and Regulation of Lipid Metabolism
Timothy F. Osborne, Sanford-Burnham Medical Research Institute, USA
The Regulation of Adipocyte Lipolysis by Insulin
Karen-Marie Pedersen, Aarhus University, Denmark
Short Talk: SorCS1, Encoded by the Alzheimer's Disease and Type 2 Diabetes Susceptibility Gene SORCS1, Is a Potent Regulator of Peripheral Insulin Sensitivity
Jeffrey A. Kohn, Emory University, USA
Short Talk: Adaptor Protein PID1 Is a Molecular Switch for LRP1 Function in Liver and Adipose Tissue
Lucia Krott, University Medical Center Hamburg-Eppendorf, Germany
Short Talk: SorCS1, Encoded by the Alzheimer’s Disease and Type 2 Diabetes Susceptibility Gene SORCS1, Is a Potent Regulator of Peripheral Insulin Sensitivity

Nutrient Control of Lipid Metabolism
*Russell A. DeBose-Boyd, University of Texas Southwestern Medical Center, USA
Matthew D. Hirshey, Duke University, USA
Mitochondrial Regulation of Lipid Metabolism

* Session Chair † Invited but not yet accepted  Program current as of November 2, 2018. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit www.keystonesymposia.org/15D6.
Marcia C. Haigis, Harvard Medical School, USA
Mitochondrial Dysfunction and Metabolic Disease

Catherine Postic, INSERM, Institut Cochin, France
LXR Protects Mice Expressing a Constitutive Isoform of ChREBP from Non-Alcoholic Steatohepatitis (NASH)

Hervé Guillou, Institut National de la Recherche Agronomique, France
Short Talk: Liver PPARalpha Is Crucial for Whole Body Energy Homeostasis and Protects from NAFLDs

Poster Session 3

THURSDAY, APRIL 23

Cellular Control of Lipid Synthesis

*Timothy F. Osborne, Sanford-Burnham Medical Research Institute, USA
Guosheng Liang, University of Texas Southwestern Medical Center, USA
Role of SREBP Pathway in Development of Hepatic Steatosis

Russell A. DeBose-Boyd, University of Texas Southwestern Medical Center, USA
Sterol and Nonsterol Signals Regulating ERAD of HMG CoA Reductase

Fabienne Foufelle, Centre de Recherches des Cordeliers, France
ER Stress Pathways in NAFLD

Jae Bum Kim, Seoul National University, Institute of Molecular Biology and Genetics, IMBG, South Korea
Short Talk: Off Switching Processes of Hepatic SREBP1c for Lipid Homeostasis upon Fasting

Shihyin Tsai, Buck Institute for Research on Aging, USA
Short Talk: Activated Muscle 4E-BP1 Signaling Improves Metabolic Parameters in Age- and Obesity-Induced Metabolic Deregulation

S.R. Murthy Madiraju, Montreal Diabetes Research Center, CR-CHUM, Canada
Short Talk: Deletion of ABHD6, a Monoacylglycerol Lipase, Induces Adipose Browning and Prevents Obesity and Type-2 Diabetes

Therapeutic Targets for Molecular Disease

*Alan D. Attie, University of Wisconsin-Madison, USA
Rosanne M. Crooke, Ionis Pharmaceuticals, Inc., USA
Antisense Inhibition of Cardiovascular Risk Factors: From Bench to Clinic

Viktoria Gusarova, Regeneron Pharmaceuticals, USA
Alirocumab, Fully Human Antibody to PCSK9, Reduces LDL-C in Preclinical and Clinical Studies

Shirly Pinto, Kallyope, USA
Therapeutic Approaches for Lipid Modulation

FRIDAY, APRIL 24

Departure